


FIGURE 1



* Part of biomarker discovery set. [†] In Panels A, C, E, and G, epithelial ovarian cancer included both invasive and borderline tumors.

FIGURE 2




FIGURE 3





FIGURE 4

Fig. 5

Different forms of ITIH4 differ in their separating power

...AGAAGSRMMNERPGVLSSRQLGLPGPPDVPDHAA YHPFRRLLALP...



Species	p value
Orig	.03
-M	NS
-MN	.04
-MNF	.005
-MNFR	NS
-MNFRP	NS
-MNFRPG	NS
-MNFRPGV	NS
-MNFRPGVL	NS

Transthyretin assays

Fig. 6






Fig. 7

Scatter plots from patient samples



* $p < .01$; ** $p < .001$

Fig. 8
Acid hydrolysis demonstrates cysteinylolation






Fig. 9




Fig. 10




Fig. 11




Fig. 12




Fig. 13




Fig. 14

Apo A1 peaks on IMAC30 Cu array (PBSIIc)

Intergen serum after enrichment on IDA-Ni peaks

WO 2005/098447

11/12

PCT/US2005/010783





Fig. 15

Apo A1 peaks on IMAC30 Cu array (PCS4000)

SAIC protocol – Intergen serum direct binding without enrichment

WO 2005/098447

12/12





Fig 1b